News

Potential blood biomarkers for AS identified in study

Proteins associated with inflammation and immune system function were identified as potential blood biomarkers for the diagnosis and monitoring of ankylosing spondylitis (AS). “Better biomarkers would address a significant unmet need both in clinic, where earlier diagnosis and referral might be improved, as well as in bettering our understanding…

Hip surgery complications increase hospital stays, costs for AS patients

Ankylosing spondylitis (AS) patients undergoing total hip replacement face longer hospital stays and higher related costs than other patients after the surgery, according to an analysis of hospital records. More complications, including anemia and infections, soon after surgery drove these increases in stays and admission-related costs, researchers noted. These…

Cosentyx shows safety, efficacy over 1 year in real-world AS study

One year of treatment with Cosentyx (secukinumab) showed safety and efficacy in a real-world study conducted in Italy, lowering disease activity among people with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Men were overall more likely than women to achieve disease remission after a year of treatment. “This…

Traditional Chinese medicine for AS may help ease pain, boost mobility

When combined with modern evidence-based medicine, treatment with the traditional Chinese herbal medicine Duhuo Jisheng decoction may help relieve pain and improve mobility in people with ankylosing spondylitis (AS), according to an analysis of clinical trial data. “Current evidence suggests that [Duhuo Jisheng decoction] combined with Western medicine is…

FDA approves higher concentration of Hyrimoz, Humira biosimilar

A high concentration formulation of Sandoz’s biosimilar Hyrimoz (adalimumab-adaz) has been approved by the U.S. Food and Drug Administration (FDA) to treat ankylosing spondylitis (AS) and other conditions. The new citrate-free formulation (100 mg/mL) is expected to be available on July 1, according to Sandoz. It’s approved for seven…